Vytrus Biotech, S.A. (FRA:V5P)

Vytrus Biotech Statistics

Total Valuation

Vytrus Biotech has a market cap or net worth of EUR 60.19 million. The enterprise value is 58.33 million.

Market Cap	60.19M
Enterprise Value	58.33M

Important Dates

The next estimated earnings date is Wednesday, March 25, 2026.

Earnings Date	Mar 25, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	7.52M
Shares Outstanding	n/a
Shares Change (YoY)	n/a
Shares Change (QoQ)	-0.44%
Owned by Insiders (%)	34.62%
Owned by Institutions (%)	16.34%
Float	3.70M

Valuation Ratios

The trailing PE ratio is 30.83 and the forward PE ratio is 22.47.

PE Ratio	30.83
Forward PE	22.47
PS Ratio	7.44
PB Ratio	6.76
P/TBV Ratio	13.35
P/FCF Ratio	22.29
P/OCF Ratio	20.34
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 24.61, with an EV/FCF ratio of 21.60.

EV / Earnings	29.88
EV / Sales	7.21
EV / EBITDA	24.61
EV / EBIT	27.72
EV / FCF	21.60

Financial Position

The company has a current ratio of 3.08, with a Debt / Equity ratio of 0.16.

Current Ratio	3.08
Quick Ratio	2.78
Debt / Equity	0.16
Debt / EBITDA	0.60
Debt / FCF	0.53
Interest Coverage	20.45

Financial Efficiency

Return on equity (ROE) is 24.85% and return on invested capital (ROIC) is 13.73%.

Return on Equity (ROE)	24.85%
Return on Assets (ROA)	11.04%
Return on Invested Capital (ROIC)	13.73%
Return on Capital Employed (ROCE)	18.33%
Revenue Per Employee	218,523
Profits Per Employee	52,763
Employee Count	37
Asset Turnover	0.68
Inventory Turnover	1.53

Taxes

In the past 12 months, Vytrus Biotech has paid 94,100 in taxes.

Income Tax	94,100
Effective Tax Rate	4.60%

Stock Price Statistics

The stock price has increased by +231.02% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+231.02%
50-Day Moving Average	6.07
200-Day Moving Average	3.96
Relative Strength Index (RSI)	63.68
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Vytrus Biotech had revenue of EUR 8.09 million and earned 1.95 million in profits.

Revenue	8.09M
Gross Profit	7.32M
Operating Income	2.10M
Pretax Income	2.05M
Net Income	1.95M
EBITDA	2.37M
EBIT	2.10M
Earnings Per Share (EPS)	n/a

Balance Sheet

The company has 3.29 million in cash and 1.42 million in debt, giving a net cash position of 1.87 million.

Cash & Cash Equivalents	3.29M
Total Debt	1.42M
Net Cash	1.87M
Net Cash Per Share	n/a
Equity (Book Value)	8.90M
Book Value Per Share	n/a
Working Capital	3.53M

Cash Flow

In the last 12 months, operating cash flow was 2.96 million and capital expenditures -258,257, giving a free cash flow of 2.70 million.

Operating Cash Flow	2.96M
Capital Expenditures	-258,257
Free Cash Flow	2.70M
FCF Per Share	n/a

Margins

Gross margin is 90.53%, with operating and profit margins of 26.02% and 24.15%.

Gross Margin	90.53%
Operating Margin	26.02%
Pretax Margin	25.31%
Profit Margin	24.15%
EBITDA Margin	29.31%
EBIT Margin	26.02%
FCF Margin	33.40%

Dividends & Yields

Vytrus Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	3.24%
FCF Yield	4.49%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	8